Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Pulse Biosciences, Inc.    PLSE

PULSE BIOSCIENCES, INC.

(PLSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Pulse Biosciences : Schedules Third Quarter 2020 Financial Results Conference Call for November 9, 2020

10/28/2020 | 03:09pm EST

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter 2020 after market close on Monday, November 9, 2020. Company management will host a corresponding conference call beginning at 1:30pm PT.

Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit www.pulsebiosciences.com.

Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.


© Business Wire 2020
All news about PULSE BIOSCIENCES, INC.
01/12PULSE BIOSCIENCES : Updates on CellFX System Regulatory and Clinical Study Progr..
BU
01/05PULSE BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
01/05PULSE BIOSCIENCES, INC. : Announces Redemption of Warrants
BU
2020PULSE BIOSCIENCES : Grants Equity Incentive Awards To New Employees
BU
2020PULSE BIOSCIENCES : Presents Update on Nano-Pulse Stimulation™ Technology ..
BU
2020PULSE BIOSCIENCES : to Participate in Upcoming Investor Conferences
BU
2020PULSE BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
2020PULSE BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financi..
AQ
2020PULSE BIOSCIENCES : Reports Third Quarter 2020 Financial Results
BU
2020PULSE BIOSCIENCES : Schedules Third Quarter 2020 Financial Results Conference Ca..
BU
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 683 M 683 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 263x
Nbr of Employees 82
Free-Float 50,4%
Chart PULSE BIOSCIENCES, INC.
Duration : Period :
Pulse Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULSE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 16,00 $
Last Close Price 26,94 $
Spread / Highest target -40,6%
Spread / Average Target -40,6%
Spread / Lowest Target -40,6%
Managers and Directors
NameTitle
Darrin R. Uecker President, Chief Executive Officer & Director
Robert William Duggan Chairman
Edison Manuel Vice President-Operations
Sandra A. Gardiner CFO, Secretary, Treasurer & Executive VP-Finance
Richard Nuccitelli Chief Science Officer
Sector and Competitors